Login to Your Account

Clinic Roundup

Friday, September 27, 2013

• Chimerix Inc., of Durham, N.C., published results of a Phase II study of brincidofovir (CMX001) for cytomegalovirus (CMV) in hematopoietic cell transplant (HCT) recipients in the Sept. 26, 2013, issue of the New England Journal of Medicine. The drug has shown broad-spectrum antiviral activity against double-stranded DNA viruses, including CMV.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription